JP2017534604A5 - - Google Patents

Download PDF

Info

Publication number
JP2017534604A5
JP2017534604A5 JP2017518487A JP2017518487A JP2017534604A5 JP 2017534604 A5 JP2017534604 A5 JP 2017534604A5 JP 2017518487 A JP2017518487 A JP 2017518487A JP 2017518487 A JP2017518487 A JP 2017518487A JP 2017534604 A5 JP2017534604 A5 JP 2017534604A5
Authority
JP
Japan
Prior art keywords
composition
composition according
sirolimus
carrier
micrograms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017518487A
Other languages
English (en)
Japanese (ja)
Other versions
JP6679584B2 (ja
JP2017534604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/054550 external-priority patent/WO2016057712A1/en
Publication of JP2017534604A publication Critical patent/JP2017534604A/ja
Publication of JP2017534604A5 publication Critical patent/JP2017534604A5/ja
Application granted granted Critical
Publication of JP6679584B2 publication Critical patent/JP6679584B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017518487A 2014-10-07 2015-10-07 肺高血圧症を処置するための吸入可能なラパマイシン配合物 Active JP6679584B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462060988P 2014-10-07 2014-10-07
US62/060,988 2014-10-07
US201562144145P 2015-04-07 2015-04-07
US62/144,145 2015-04-07
PCT/US2015/054550 WO2016057712A1 (en) 2014-10-07 2015-10-07 An inhalable rapamycin formulation for the treatment of pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2017534604A JP2017534604A (ja) 2017-11-24
JP2017534604A5 true JP2017534604A5 (enExample) 2018-11-08
JP6679584B2 JP6679584B2 (ja) 2020-04-15

Family

ID=54360545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518487A Active JP6679584B2 (ja) 2014-10-07 2015-10-07 肺高血圧症を処置するための吸入可能なラパマイシン配合物

Country Status (12)

Country Link
US (3) US20170304276A1 (enExample)
EP (1) EP3209330B1 (enExample)
JP (1) JP6679584B2 (enExample)
KR (1) KR20170095807A (enExample)
CN (1) CN107249576A (enExample)
AU (1) AU2015330905B2 (enExample)
BR (1) BR112017006842A2 (enExample)
CA (1) CA2963085C (enExample)
IL (1) IL251385B (enExample)
MX (1) MX389399B (enExample)
RU (1) RU2732908C2 (enExample)
WO (1) WO2016057712A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102256576B1 (ko) 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
PL3125875T3 (pl) 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
IL319790A (en) 2016-05-05 2025-05-01 Liquidia Tech Inc Terpostinil in dry powder form for the treatment of pulmonary hypertension
HUE058320T2 (hu) * 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
RU2020134124A (ru) 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
EP3810091A4 (en) * 2018-05-22 2022-03-02 Abraxis BioScience, LLC METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION
CN113795287A (zh) * 2019-03-19 2021-12-14 阿布拉科斯生物科学有限公司 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
KR20250152464A (ko) * 2024-04-16 2025-10-23 한미약품 주식회사 흡입제 조성물

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517482A (en) 1949-04-09 1950-08-01 Sharp & Dohme Inc Inhaler
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
DE3345722A1 (de) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
GB8909891D0 (en) * 1989-04-28 1989-06-14 Riker Laboratories Inc Device
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
AU688782B2 (en) 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
RU2147226C1 (ru) 1994-09-29 2000-04-10 Квадрант Хэлткэа (Ю Кей) Лимитед Высушенные распылением микрочастицы как терапевтические носители
US5635161A (en) 1995-06-07 1997-06-03 Abbott Laboratories Aerosol drug formulations containing vegetable oils
DE19523516C1 (de) * 1995-06-30 1996-10-31 Asta Medica Ag Inhalator zum Verabreichen von Medikamenten aus Blisterpackungen
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6451784B1 (en) 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US20040039047A1 (en) 1998-08-11 2004-02-26 Mark Zamoyski Compositions and methods for treating lung cancers
EP1104760B1 (en) * 1999-12-03 2003-03-12 Pfizer Products Inc. Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
CA2456746A1 (en) 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
EP1424898A4 (en) 2001-08-20 2008-04-02 Transave Inc TREATMENT OF CANCER BY INHALATION OF STABLE FORMULATIONS CONTAINING PLATINUM
CA2486622A1 (en) 2002-05-20 2003-12-04 Research Development Foundation Aerosol drug inhibition of lung metastases
US20050070567A1 (en) 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
AU2003269989B8 (en) * 2002-08-21 2009-11-12 Norton Healthcare Ltd. Inhalation composition
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
UA83484C2 (uk) 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR043504A1 (es) 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
BRPI0516170A (pt) 2004-09-29 2008-08-26 Cordis Corp formas de dosagens farmacêuticas estáveis e amorfas de compostos de rapamicina
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
FR2882366B1 (fr) 2005-02-18 2008-04-18 Coletica Sa Polymere reticule de carbohydrate, notamment a base de polysaccharides et/ou de polyols
MX2007010716A (es) 2005-03-02 2008-01-16 Wyeth Corp Purificacion de rapamicina.
BRPI0608573A2 (pt) * 2005-03-08 2017-07-25 Lifecycle Pharma As Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
WO2006101972A2 (en) 2005-03-17 2006-09-28 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
CN1883474A (zh) 2005-06-22 2006-12-27 华北制药集团新药研究开发有限责任公司 一种含大环内酯类化合物和多孔水不溶性亲水性载体的组合物
US7446096B2 (en) 2005-12-19 2008-11-04 Industrial Technology Research Institute Glutathione based delivery system
AU2006331874A1 (en) 2005-12-20 2007-07-05 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
TR201807065T4 (tr) 2006-02-02 2018-06-21 Novartis Ag Tüberöz sklerozis tedavisi.
GB0602123D0 (en) 2006-02-02 2006-03-15 Novartis Ag Organic compounds
RU2010104916A (ru) 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
MX2009005012A (es) 2006-11-10 2009-09-07 Biocon Ltd Una forma pura de rapamicina y procedimiento para la recuperacion y purificacion de la misma.
EP2066321A2 (en) 2006-11-20 2009-06-10 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080138405A1 (en) 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
US9370508B2 (en) 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
EP3326630A3 (en) * 2007-05-03 2018-08-29 Abraxis BioScience, LLC Methods and compositions for treating pulmonary hypertension
DK2252275T3 (en) 2008-02-13 2018-03-05 Univ Texas CREATED NON-OPEN FLOCKS OF ANISOTROPIC PARTICLES FOR IMPROVED TRANSPORT INTO THE Lungs
ES2645692T3 (es) * 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
EP2389162A1 (en) 2009-01-26 2011-11-30 Teva Pharmaceutical Industries Ltd Processes for coating a carrier with microparticles
US20100196483A1 (en) 2009-02-04 2010-08-05 Activaero Gmbh Research & Development Method for treatmentof severe and uncontrollable asthma
GB0905818D0 (en) 2009-04-06 2009-05-20 Airbus Uk Ltd Coupling assembly
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
GB0908129D0 (en) 2009-05-12 2009-06-24 Innovata Ltd Composition
US9248110B2 (en) * 2010-03-18 2016-02-02 Steven Lehrer Compositions and methods of treating and preventing lung cancer and lymphangioleiomyomatosis
PT105058B (pt) * 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
US20110318277A1 (en) 2010-06-25 2011-12-29 APT Pharmaceuticals, Inc. University of Maryland, Baltimore Tacrolimus compositions for aerosol administration
US20140037548A1 (en) * 2010-06-28 2014-02-06 The Board Of Trustees Of The Leland Standford Junior University Treatment and prevention of diffuse parenchymal lung disease by selective active-site mTOR inhibitors
JP2013538830A (ja) 2010-09-27 2013-10-17 マイクロドース セラピューテクス,インコーポレイテッド 吸入を用いる疾患治療のための方法及び組成物
CN102670518B (zh) * 2011-03-14 2014-08-20 齐鲁制药有限公司 一种难溶性药物球形颗粒的制备方法
US20140067548A1 (en) 2012-08-31 2014-03-06 Sap Ag Saving on device functionality for business calendar
CN112075911A (zh) 2013-03-28 2020-12-15 恩多巧爱思股份有限公司 紧凑的多观察元件内窥镜系统
KR102256576B1 (ko) * 2013-10-08 2021-05-27 에이아이 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RU2016136348A (ru) * 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
PL3125875T3 (pl) 2014-04-04 2023-11-20 AI Therapeutics, Inc. Nadający się do inhalacji preparat rapamycyny do leczenia stanów związanych z wiekiem
DE102014005466A1 (de) 2014-04-12 2015-10-15 Klaus Düring Verfahren zur Gewinnung von Napin und Cruciferin oder einem Gemisch davon aus Raps
AU2015330905B2 (en) 2014-10-07 2021-02-25 AI Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) * 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
CN108039392A (zh) 2017-11-06 2018-05-15 北京汉能薄膜发电技术有限公司 铜铟镓硒化合物、油墨及其薄膜吸收层制备方法

Similar Documents

Publication Publication Date Title
JP2017534604A5 (enExample)
RU2016136348A (ru) Рапамицин для лечения лимфангиолейомиоматоза
RU2016117764A (ru) Рапамицин для лечения лимфангиолейомиоматоза
RU2017115990A (ru) Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
RU2016143365A (ru) Рапамицин-содержащая композиция, вводимая путем ингаляции для лечения возрастных заболеваний
JP2017509684A5 (enExample)
US20150272874A1 (en) Pulmonary disease-specific therapeutic agent
CN103002877A (zh) 作为缓解疾病的抗风湿性药(dmard)和抗癌药剂的甲氨蝶呤的持续释放制剂
US20170246118A1 (en) Long acting pharmaceutical compositions
JP2018150339A (ja) パーキンソン病の迅速な軽減のためのレボドパ製剤
EP3307236A1 (en) Process for the preparation of porous microparticles
CN113271960A (zh) 干粉吸入配制品及其用于治疗肺的用途
WO2016055544A1 (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
AU2013248242A1 (en) Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
WO2021195580A1 (en) Prevention and treatment of coronavirus-associated diseases using an apelin peptide and formulations thereof
JP7654544B2 (ja) ベダキリンの組成物、それらを含む組み合わせ、それらを調製するための方法、それらを含む使用及び治療方法
CN117940128A (zh) 异丁司特用于防止眼癌转移
ES2973119T3 (es) Combinación de ibudilast e interferón-beta y métodos de uso
JP2019038857A (ja) レボドパの血漿濃度の患者間のばらつきの低減
CN112533664A (zh) 使用气雾剂诊断Brugada综合征的方法
PATIL et al. Liposomal dry powder inhaler: novel pulmonary targeted drug delivery system for the treatment of lung cancer
Reddy et al. Principles of drug release in various dosage forms
Saigal et al. Controlled release inhalable polymeric microspheres for treatment of pulmonary arterial hypertension
WO2021195581A1 (en) Aerosolized formulations of an apelin peptide and uses thereof
Albalawi et al. Innovations in Respiratory Therapy: Addressing Pulmonary Fibrosis with Inhalation Techniques